About the UK Myeloma Research Alliance (UKMRA)

The UK Myeloma Research Alliance is the national organisation that oversees clinical research for multiple myeloma and related conditions.  It is aligned with the National Cancer Research Institute (NCRI) Myeloma Working Group which sits within the NCRI Haem-Onc Group.  The purpose of the UKMRA is to identify research needs, design and deliver clinical trials and other research for the benefit of patients with myeloma and to advance scientific research.

The UKMRA is led by an elected Senior Leadership team which sets the strategy for the wider group.  Wider group membership is open to clinicians, scientists and other health care professionals that share a common aim.

The UKMRA has been successful in delivering high impact trials that have influenced international practice and continues to innovate and deliver cutting edge research.

Science Forum

The UKMRA Science Forum has been created to bring together UK myeloma scientists to foster new collaborations, and to encourage and inspire the next generation of researchers. This new and exciting initiate is led by Dr Michelle Lawson and Dr Sarah Gooding, the Translational UKMRA lead. The inaugural Science Forum meeting ran in parallel during the Autumn Day in November. There were a number of UK based speakers including Prof John Christianson, Dr Sarah Dimeloe, Dr Alana Green, Dr Nick Crump and Dr Eileen Boyle. From this meeting we have created a mailing list, which we encourage you to join. The idea is to develop a science community that will support, mentor, share job opportunities and promote myeloma focused education. If you or your colleagues would like to join this mailing list, please email Wendy.

Pathway Optimisation Group

One of the UKMRA’s central aims is to generate supportive and substantive evidence to inform better care for myeloma patients in the NHS. For this goal, the UKMRA is working jointly with the UKMS Pathway Optimisation Group, which performs rolling, long-term horizon scanning and demand signalling to identify areas of unmet patient need and evidence requirements for improved access. The UKMS Pathway Optimisation group also utilises alternative commissioning routes, where evidence is not suitable or eligible for evaluation via the main, commercial route via NICE. Through their joint strategy, UKMRA and UKMS therefore develop forward-looking, patient-focussed access strategies for patients with myeloma in the UK and elsewhere. In case of any queries about the Pathway Optimisation Group, please contact .

Full membership list of the UKMRA can be seen here  Click Here

UKMRA Senior Leadership Team

Dr Rakesh Popatat


Dr Martin Kaiser


Prof David Cairns

Trial Design Lead

Sarah Gooding

Translational Lead

Dr Matthew Jenner

Governance Lead

Prof. Kwee Yong

Industry Lead

Prof Gordon Cook

Past Chair (Honorary role)

List all other members and affiliations

Our current trials portfolio can be viewed here.  Click here